Australia Allows Industry Collaboration To Continue
GBMA And Medicines Australia Get One-Year Extension From ACCC
Executive Summary
Australia’s competition authority has extended the arrangements allowing local off-patent industry body the GBMA to closely collaborate with brand organization Medicines Australia to co-ordinate supply against the backdrop of the ongoing COVID-19 pandemic.
You may also be interested in...
Australia's Competition Regulator Authorizes Another Year Of Close Collaboration
Australian off-patent industry association GBMA and brand body Medicines Australia can continue to collaborate closely as part of work to mitigate shortages in the context of the COVID-19 pandemic, the Australian Competition and Consumer Commission has decided, extending an existing authorization by a further year.
Another Year Of Close Collaboration Authorized In Australia
Australian off-patent industry association the GBMA and brand body Medicines Australia can continue to collaborate closely as part of work to mitigate shortages in the context of the COVID-19 pandemic, the ACCC has decided, extending an existing authorization by a further year.
Fresh Australian Industry Pact Will Insure Against Shortages
A fresh five-year strategic agreement struck between Australian off-patent industry association the GBMA and the country’s government offers sustainability and stability for Australia’s generics sector, with the body committing to holding safety stocks of certain drugs within the country to protect against potential shortages in the context of the COVID-19 pandemic.